Compare Gilead Sciences, Inc. (GILD) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Uranium Energy Corp — how do they compare? Gilead Sciences, Inc. trades at $150.86 (market cap $182.40B), while Uranium Energy Corp trades at $9.2 (market cap $4.53B). The key difference: Gilead Sciences, Inc. is far larger — about 40.3× Uranium Energy Corp's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Uranium Energy Corp for 37 Days on average.
| GILD | UEC | |
|---|---|---|
Market Cap | $182.40B | $4.53B |
Volume | 4,469,821 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $155.80 | $20.14 |
52-Week Low | $116.74 | $9.04 |
Typical Hold Time | 111 Days | 37 Days |
Enterprise Value | $205.46B | $4.03B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
UEC trades at $9.27, down 2.11% on the day, amid a bearish technical outlook with 18 sell signals versus 2 buy signals. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and a negative net income margin of -368.62%. Recent news highlights operational expansion with two in-situ recovery mines ramping up production, supported by strong institutional analyst sentiment with 7 buy ratings and a consensus price target of $16.06.
The investment case balances Wall Street optimism against weak profitability and cash burn. Upside is driven by exposure to growing U.S. uranium demand and multi-mine expansion, but high execution risk, sustained losses, and negative operating cash flow pose significant threats to shareholder value. The stock's trajectory hinges on translating production growth into sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
